Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)
- Some children experience a sudden onset of symptoms similar to those found in obsessive-compulsive disorder that may be caused by the body's reaction to an infection with streptococcal bacteria, most commonly seen as strep throat or scarlet fever. When the body's immune system reacts against brain cells following a streptococcal infection, the condition is known as PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections). The immune system response can be inactivated by treatment with a drug known as intravenous immunoglobulin (IVIG). Because there is insufficient research on IVIG's effects on the immune system of children with PANDAS, including whether IVIG is helpful in treating obsessive-compulsive symptoms related to PANDAS, researchers are interested in examining whether IVIG is an appropriate treatment for PANDAS and its associated symptoms.
- To test the safety and effectiveness of intravenous immunoglobulin for the treatment of obsessive-compulsive disorder in children with PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection).
- Children between 4 and 12 years of age who have obsessive-compulsive disorder (with or without a tic disorder) with sudden onset of symptoms following Group A streptococcal bacterial infections.
- Participants will be screened by telephone to obtain medical history and other information, followed by in-person screening at the National Institutes of Health Clinical Center.
- Participants will be admitted to the hospital to receive 2 days of infusions of either IVIG or a placebo. Frequent blood samples, imaging studies, and other tests will be performed during this visit.
- Six weeks after the inpatient stay, participants will return for further blood samples and other tests. Participants who did not receive the study drug, or who received the drug but did not respond to the initial IVIG infusion, will have the option to receive IVIG at this time.
- Followup visits will take place 3 months and 6 months after the first evaluation, followed by yearly follow-ups for 3 additional years.
Drug: Gamunex Intravenous Immunoglobulin
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)|
- Active IVIG will be significantly superior to sham IVIG in reducing OC symptoms and providing global relief of neuropsychiatric symptomatology. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- The degree of treatment response is expected to correlate with the percentage reduction in Abs titers following IVIG administration. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by changes on MRI [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||January 2016|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
|Experimental: Group A||
Drug: Gamunex Intravenous Immunoglobulin
2.0 gm/kg total, IV (in the vein), over 2 days
|Placebo Comparator: Group B||
Normal saline, IV (in the vein), over 2 days
This study is designed to test the safety and efficacy of intravenous immunoglobulin (IVIG) for the treatment of obsessive-compulsive disorder (OCD) symptoms in children with PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection).
Thirty-two male and female children with severe obsessive-compulsive symptoms related to a new onset or first recurrence of symptoms consistent with the PANDAS subtype of OCD.
This is a multi-site double-blind placebo-controlled trial. Potential subjects will be screened in person at NIMH, and there will be remote video corroboration by a team of collaborators at Yale University. Eligible subjects will be admitted to the 1NW pediatrics inpatient unit at the Clinical Center for further assessment, randomization, and study drug administration according to protocol. Subjects who fail to improve 6 weeks after blinded IVIG/placebo administration (1.0 gm/kg/day of IVIG on two consecutive days; total dose 2.0 gm/kg) will be eligible to receive open-label IVIG.
Primary: Improvement in obsessions, compulsions, and other neuropsychiatric symptoms.
- Reduction of titers of cross-reactive antibodies (Abs)
- Resolution of basal ganglia inflammation (as measured by pre-/post-changes in MRI volumetric scans and inflammatory sequences)
- Normalization of selected serum and CSF cytokines
|Contact: Paul J Grant, M.D.||(301) email@example.com|
|Contact: Susan E Swedo, M.D.||(301) firstname.lastname@example.org|
|United States, Connecticut|
|Yale University Child Study Center||Recruiting|
|New Haven, Connecticut, United States, 06510-8005|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Susan E Swedo, M.D.||National Institute of Mental Health (NIMH)|